Stockreport

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance [Financial P...

Theratechnologies Inc. - Common Shares  (THTX) 
PDF Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens MONTREAL, Oct. 17, 2024 [Read more]